Does my hon. Friend agree that we have to be careful not to discourage drug companies from doing research, particularly into those rarer illnesses, because they would not see a financial return?
Health Service Medical Supplies (Costs) Bill
Proceeding contribution from
Mark Tami
(Labour)
in the House of Commons on Monday, 24 October 2016.
It occurred during Debate on bills on Health Service Medical Supplies (Costs) Bill.
About this proceeding contribution
Reference
616 c86Session
2016-17Chamber / Committee
House of Commons chamberSubjects
Librarians' tools
Timestamp
2020-04-14 16:59:33 +0100
URI
http://hansard.intranet.data.parliament.uk/Commons/2016-10-24/16102435000038
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2016-10-24/16102435000038
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2016-10-24/16102435000038